HARBIN, China, Dec. 14, 2010 /PRNewswire-Asia-FirstCall/ —
China Botanic Pharmaceutical Inc. (AMEX:
CBP) (“China Botanic” or the “Company”), a developer,
manufacturer and distributor of botanical products,
bio-pharmaceuticals and traditional Chinese medicines (“TCM”),
today announced that as of fiscal year ending October 31, 2010, the
Company’s new all-natural anti-depressant and nerve regulation
product – Compound Schisandra Tablets (“Schisandra Tablets”), a
single plant based medicine, has achieved sales of RMB 3.0 million
(or $0.5 million) since its launch in July 2010. The sales are in
line with management’s original estimates.
Schisandra, also known as magnolia vine, has been clinically
proven to provide significant benefits to the functioning and
regulation of the central nervous system and respiratory systems.
According to the traditional Chinese pharmacopoeia, Schisandra is
used as a remedy for many ailments, such as those of the kidneys,
insomnia and heart palpitations, and is also widely used as
treatment for neurasthenia (a term most commonly used in
Traditional Chinese medicine to denote a complex of symptoms
characterized by chronic fatigue and weakness, loss of memory, and
generalized aches and pains).
“Compound Schisandra Tablets complements our existing
anti-depressant and nerve regulation Ginseng based product series,
and strengthens China Botanic’s goal to be the world’s leading
company specializing in plant-based medicine,” said Mr. Shaoming
Li, Chairman and Chief Executive Officer of China Botanic.. “We are
pleased with the initial strong sales and market acceptance of our
Schisandra Tablets, which are in line with our sales forecast. This
reflects well on our thorough market research and sales and
marketing strategy. We will continue to develop market oriented
all-natural plant based products to capitalize on the attractive
market opportunities.”<
‘/>”/>
SOURCE